INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 187 filers reported holding INOVIO PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $2,171,300 | -53.0% | 2,647,927 | -10.6% | 0.02% | -61.5% |
| Q4 2022 | $4,622,455 | +13.4% | 2,963,112 | +25.4% | 0.04% | -9.3% |
| Q3 2022 | $4,077,000 | +13.8% | 2,363,189 | +14.1% | 0.04% | +30.3% |
| Q2 2022 | $3,584,000 | -49.6% | 2,071,803 | +4.6% | 0.03% | -21.4% |
| Q1 2022 | $7,108,000 | +15.6% | 1,979,825 | +60.7% | 0.04% | +31.2% |
| Q4 2021 | $6,148,000 | +14.7% | 1,232,071 | +64.6% | 0.03% | -13.5% |
| Q3 2021 | $5,360,000 | -12.9% | 748,655 | +12.8% | 0.04% | -5.1% |
| Q2 2021 | $6,155,000 | -4.1% | 663,948 | -4.0% | 0.04% | -11.4% |
| Q1 2021 | $6,415,000 | +424.1% | 691,280 | +399.9% | 0.04% | +266.7% |
| Q4 2020 | $1,224,000 | -46.4% | 138,275 | -29.8% | 0.01% | -57.1% |
| Q3 2020 | $2,283,000 | +15.5% | 196,842 | +168.4% | 0.03% | 0.0% |
| Q2 2020 | $1,977,000 | +181.2% | 73,347 | -61.1% | 0.03% | +154.5% |
| Q1 2019 | $703,000 | – | 188,557 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Triatomic Management LP | 235,000 | $405,000 | 0.23% |
| Green Alpha Advisors, LLC | 147,380 | $254,000 | 0.22% |
| Financial Advocates Investment Management | 14,161 | $628,000 | 0.05% |
| Virtus ETF Advisers LLC | 72,540 | $125,000 | 0.05% |
| Cedar Brook Financial Partners, LLC | 88,750 | $153,094 | 0.05% |
| Rafferty Asset Management, LLC | 2,363,189 | $4,077,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 352,721 | $608,000 | 0.04% |
| CAXTON ASSOCIATES LP | 130,728 | $226,000 | 0.03% |
| Keystone Financial Group | 74,058 | $128,000 | 0.03% |
| Virtu Financial LLC | 130,829 | $226,000 | 0.02% |